Evidence map›Paper›PMID 39483205›Full record

ArticleFrontiers in computational neuroscience2024

A combinatorial deep learning method for Alzheimer's disease classification-based merging pretrained networks.

Houmem Slimi, Ala Balti, Sabeur Abid, Mounir Sayadi

Abstract read
In one paragraph

Article in Frontiers in computational neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Houmem SlimiResearch Laboratory SIME, ENSIT, University of Tunis, Tunis, Tunisia.
Ala BaltiResearch Laboratory SIME, ENSIT, University of Tunis, Tunis, Tunisia.
Sabeur AbidResearch Laboratory SIME, ENSIT, University of Tunis, Tunis, Tunisia.
Mounir SayadiResearch Laboratory SIME, ENSIT, University of Tunis, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. Despite significant research, AD remains incurable, highlighting the critical need for early diagnosis and intervention to improve patient outcomes. Timely detection plays a crucial role in managing the disease more effectively. Pretrained convolutional neural networks (CNNs) trained on large-scale datasets, such as ImageNet, have been employed for AD classification, providing a head start for developing more accurate models. Methods: This paper proposes a novel hybrid deep learning approach that combines the strengths of two specific pretrained architectures. The proposed model enhances the representation of AD-related patterns by leveraging the feature extraction capabilities of both networks. We validated this model using a large dataset of MRI images from AD patients. Performance was evaluated in terms of classification accuracy and robustness against noise, and the results were compared to several commonly used models in AD detection. Results: The proposed hybrid model demonstrated significant performance improvements over individual models, achieving an accuracy classification rate of 99.85%. Comparative analysis with other models further revealed the superiority of the new architecture, particularly in terms of classification rate and resistance to noise interference. Discussion: The high accuracy and robustness of the proposed hybrid model suggest its potential utility in early AD detection. By improving feature representation through the combination of two pretrained networks, this model could provide clinicians with a more reliable tool for early diagnosis and monitoring of AD progression. This approach holds promise for aiding in timely diagnoses and treatment decisions, contributing to better management of Alzheimer's disease.

Indexed as

Alzheimer’s disease (AD)data augmentation (DA)evaluation metrics (EM)pretrained networks (PN)SMOTE

Identifiers

PMID39483205
PMCPMC11525984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.